WHO: Vaccine Partnerships Crucial by 2027

The idea that governments or private companies should go it alone on vaccine development is a dangerous relic. For a global health system to be strong, fast, and fair, it has to integrate the strengths of both the public and private sectors, especially when it comes to making vaccines. The World Health Organization (WHO) has been saying this for years, and expanding these public-private partnerships is simply what’s required for our collective future.

The Indispensable Teamwork of Public and Private Strengths

The case for public-private teamwork on vaccines is written in the hard lessons of our recent global health crises. Just think about how quickly the COVID-19 vaccines were developed. Governments fronted unprecedented amounts of cash and cleared regulatory hurdles, but it was the pharma companies, with their agile R&D teams, that actually got the vaccines designed and produced in record time. The private sector has the specialized scientists, the expensive tech platforms, and the massive manufacturing plants that public agencies just don’t have. On the other hand, governments provide the basic research funding, the rules of the road, and the purchasing power that makes it less risky for a company to invest millions, which in turn ensures the public gets access. That pipeline would be a whole lot slower without this kind of teamwork.

The WHO’s own strategy for vaccine development is built on collaboration. Initiatives like the Access to COVID-19 Tools (ACT) Accelerator, despite its own set of problems, showed the sheer ambition needed to coordinate a global response from the lab bench all the way to the doctor’s office. This takes more than just writing checks. It requires sharing scientific data, technical know-how, and even factory floor time. When it all comes together, discovery speeds up. For instance, a 2023 report from the World Health Organization showed that for neglected tropical diseases, these collaborative models cut development timelines by an average of 15% compared to work done only by public or private groups. That’s a huge improvement that translates directly into lives saved and economies stabilized when an outbreak hits.

Addressing the Equity Challenge: More Than Just Speed

Critics have a fair point when they argue that partnerships with Big Pharma can put profits ahead of people, creating huge gaps in access. That’s a real concern that we have to address by being smarter about how we structure these deals. The solution is to build equity into the foundation of these partnerships, not tear them down. Take the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership launched in 2017, as an example of how to do it right. CEPI uses its funds to develop vaccines for emerging diseases, but it comes with a non-negotiable condition: the final product must be accessible to people at risk, no matter how much money they have. Since it started, CEPI has invested over $3 billion in R&D, building a portfolio of vaccine candidates with fair pricing and distribution baked into the deals. This model, where public and philanthropic money covers the risky early stages so private partners can get the drug through trials and into production, is something we can and should do more of.

The whole fight over intellectual property (IP) during health crises shows you the tension here. Some people call for getting rid of patents entirely, but the reality is more complicated and requires structured licensing and tech transfer agreements. The WTO’s TRIPS Agreement already provides a legal path for compulsory licensing, letting countries override patents in an emergency, but it’s often a nightmare to actually use. A much better strategy is to write IP-sharing clauses into the contracts from day one. For instance, if a government is putting up a lot of public money for research, it should demand that the resulting IP is licensed non-exclusively to several manufacturers, especially in lower-income countries, with reasonable terms. Is that a tricky balance to strike? Of course, but it’s entirely achievable if you have political will and transparent negotiations.

Sustaining Innovation Beyond the Crisis Cycle

One of the biggest recurring problems in vaccine development is the boom-and-bust funding cycle. Money pours in during a pandemic and then vanishes as soon as the immediate threat is gone. This kind of short-term thinking leaves us wide open for the next pathogen. Public-private partnerships can help create more sustainable funding. If governments commit to long-term financing for pandemic preparedness, they create a predictable environment where private companies are willing to invest in basic research, platform technologies, and clinical trial networks. In the U.S., the Biomedical Advanced Research and Development Authority (BARDA) has done a good job of providing this stability for medical countermeasures. We need to expand models like BARDA globally, perhaps with a dedicated WHO-backed global health security fund.

And these partnerships need to be about building manufacturing capacity, not just developing the vaccine itself. Relying on a handful of factories in a few countries was a disaster during the COVID-19 pandemic. Decentralizing vaccine production by transferring technology and setting up local manufacturing in different regions builds both equity and global resilience. When the next virus hits, having factories ready to go in multiple places will shorten supply chains and get shots into arms faster. This takes a long-term commitment from public bodies (who can provide the seed money and regulatory help) and private companies (who have the technical and operational expertise). It’s an investment in future security.

Trying to keep vaccine development in separate public or private silos is a fantasy. The sheer complexity of modern biology, the scale of global manufacturing, and the speed of public health threats demand that we work together. We need to stop the ideological arguments and get down to the practical business of building well-governed partnerships that use the best of both worlds. With its global mandate, the WHO is the right organization to broker these deals, and ignoring that fact will leave us unprepared for the next pandemic.

The Path Forward: Structured Collaboration, Not Ideological Purity

We’re past the point of debating the merits of public versus private control. The fact is, neither side has everything it takes, the resources, the expertise, the infrastructure, to tackle global health threats alone. The future of vaccine development and global health security depends on well-designed partnerships that are transparent and focused on fairness. We have to formalize these collaborations with clear goals, defined roles, and real accountability. That means getting governments to commit to long-term funding, encouraging open science, and writing equitable access clauses into every single agreement. It also means constant dialogue and trust-building with everyone involved, including civil society groups, to make sure we never lose sight of the main goal: protecting people’s health. The WHO needs to keep pushing these models and giving us the frameworks to make them work. Our health depends on it.